Acadian Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Acadian Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-125,942	Closed	-$343K	–	2057
2026 Q1	$343K	Buy	125,942 +114,830	+1,033%	+$364K	﹤0.01%	1451
2025 Q4	$41K	Buy	+11,112	New	+$35.9K	﹤0.01%	1822
2023 Q4	–	Sell	-136,346	Closed	-$131K	–	1707
2023 Q3	$131K	Buy	+136,346	New	+$197K	﹤0.01%	1268
2020 Q2	–	Sell	-1,364	Closed	-$43K	–	2253
2020 Q1	$43K	Buy	+1,364	New	+$72K	﹤0.01%	1532
2019 Q4	–	Sell	-3,956	Closed	-$145K	–	1948
2019 Q3	$145K	Sell	3,956 -13,091	-77%	-$519K	﹤0.01%	1394
2019 Q2	$793K	Buy	+17,047	New	+$801K	﹤0.01%	866
2016 Q4	–	Sell	-100	Closed	-$1K	–	1664
2016 Q3	$1K	Buy	+100	New	+$1.13K	﹤0.01%	1381

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Acadian Asset Management's ESPR Position: Q2 2026 in Review

Acadian Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 125,942 shares — an estimated $343K sold.

Acadian Asset Management first reported a position in ESPR in Q3 2016 and held it in 7 quarters. The position peaked at $793K in Q2 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Acadian Asset Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Acadian Asset Management sold 125,942 Esperion Therapeutics shares in Q2 2026, an estimated $343K.
Acadian Asset Management first reported a position in Esperion Therapeutics in Q3 2016 and held it in 7 quarters.
Acadian Asset Management's Esperion Therapeutics position peaked at $793K in Q2 2019.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.